Akero TherapeuticsAKRO
Market Cap: $1.83B
About: Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Employees: 58
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
25% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]
17% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 52
2.76% less ownership
Funds ownership: 106.55% [Q1] → 103.79% (-2.76%) [Q2]
9% less capital invested
Capital invested by funds: $1.86B [Q1] → $1.68B (-$172M) [Q2]
12% less funds holding
Funds holding: 172 [Q1] → 152 (-20) [Q2]
23% less call options, than puts
Call options by funds: $5.99M | Put options by funds: $7.75M
54% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 37
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Ed Arce 42% 1-year accuracy 61 / 144 met price target | 89%upside $50 | Buy Reiterated | 12 Aug 2024 |
HC Wainwright & Co. Ed Arce 42% 1-year accuracy 61 / 144 met price target | 89%upside $50 | Buy Reiterated | 11 Jun 2024 |
Financial journalist opinion
Based on 3 articles about AKRO published over the past 30 days